Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Transcriptional Regulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SUB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SUB1 Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for biophysical binding assays. |
View SUB1 Products |
| Gene Delivery | SUB1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View SUB1 Products |
| Benchmark Ab | Anti-SUB1 Recombinant Antibody High-specificity positive control for Western Blot, IP, and ChIP assays. |
View SUB1 Products |
| Validator | SUB1 siRNA Set For target knockdown verification and functional rescue assays. |
View SUB1 Products |
| Related Target A | POLR2A RNA Polymerase II subunit interacts directly with SUB1 during transcription initiation and elongation. |
View POLR2A Products |
| Related Target B | EP300 Histone acetyltransferase that acetylates SUB1, modulating its double-stranded DNA binding affinity. |
View EP300 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Engagement | Sequence Verified, high-purity recombinant SUB1 proteins optimized for SPR, MST, and FP assays. |
| Transcriptional Activity Readouts | Lentivirus-mediated stable cell line construction ensuring consistent physiological expression levels. |
| Lack of Controls | Recombinant Benchmark Antibodies included to guarantee reproducible assay baselines. |
| Off-Target False Positives | Validated siRNA sets included for target-specific knockdown control. |
Live SUB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of transcriptional coactivators has emerged as a powerful front in oncology. SUB1 (also known as PC4), a crucial mediator of transcription initiation and elongation, is increasingly recognized as a key driver of tumor progression, metastasis, and therapy resistance in multiple solid tumors, including prostate and breast cancers. The race for SUB1 therapeutics is intensifying, with major players shifting focus from traditional global transcriptional inhibitors to targeted small molecules and protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the SUB1-DNA interface and its protein-protein interactions (PPI) with RNA Polymerase II.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Medical Centers, Biotech Startups | Prostate Cancer, Glioma, NSCLC | Epitope/Domain-specific binding assays (Need high-purity recombinant SUB1) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory Solid Tumors | Ternary complex formation validation (Need sequence-verified SUB1 and target-specific antibodies) |
| RNAi / Oligonucleotides | RNA Therapeutics Specialists | Advanced Metastatic Cancers | Knockdown efficiency and phenotypic rescue (Need validated siRNA / Lentivirus) |